Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease

Rajat Garg; Manik Aggarwal; Abdul Mohammed; Jean Paul Achkar; Bret Lashner; Jessica Philpott; Benjamin Cohen; Taha Qazi; Florian Rieder; Miguel Regueiro; Benjamin Click

doi:10.1007/s12664-023-01391-3

Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease

Rajat Garg, Manik Aggarwal, Abdul Mohammed, Jean Paul Achkar, Bret Lashner, Jessica Philpott, Benjamin Cohen, Taha Qazi, Florian Rieder, Miguel Regueiro, Benjamin Click

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.

Original language	English
Pages (from-to)	718-723
Number of pages	6
Journal	Indian Journal of Gastroenterology
Volume	42
Issue number	5
DOIs	https://doi.org/10.1007/s12664-023-01391-3
State	Published - Oct 2023
Externally published	Yes

Keywords

Biologics
Crohn’s disease
Elderly
Inflammatory bowel diseases
Ustekinumab
Vedolizumab

Access to Document

10.1007/s12664-023-01391-3

Cite this

@article{82b27c6409ed4957ab16fac255c89689,

title = "Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn{\textquoteright}s disease",

abstract = "Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn{\textquoteright}s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.",

keywords = "Biologics, Crohn{\textquoteright}s disease, Elderly, Inflammatory bowel diseases, Ustekinumab, Vedolizumab",

author = "Rajat Garg and Manik Aggarwal and Abdul Mohammed and Achkar, {Jean Paul} and Bret Lashner and Jessica Philpott and Benjamin Cohen and Taha Qazi and Florian Rieder and Miguel Regueiro and Benjamin Click",

note = "Publisher Copyright: {\textcopyright} 2023, Indian Society of Gastroenterology.",

year = "2023",

month = oct,

doi = "10.1007/s12664-023-01391-3",

language = "English",

volume = "42",

pages = "718--723",

journal = "Indian Journal of Gastroenterology",

issn = "0254-8860",

publisher = "Indian Society of Gastroenterology",

number = "5",

}

TY - JOUR

T1 - Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease

AU - Garg, Rajat

AU - Aggarwal, Manik

AU - Mohammed, Abdul

AU - Achkar, Jean Paul

AU - Lashner, Bret

AU - Philpott, Jessica

AU - Cohen, Benjamin

AU - Qazi, Taha

AU - Rieder, Florian

AU - Regueiro, Miguel

AU - Click, Benjamin

PY - 2023/10

Y1 - 2023/10

N2 - Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.

AB - Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.

KW - Biologics

KW - Crohn’s disease

KW - Elderly

KW - Inflammatory bowel diseases

KW - Ustekinumab

KW - Vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85166360235&partnerID=8YFLogxK

U2 - 10.1007/s12664-023-01391-3

DO - 10.1007/s12664-023-01391-3

M3 - Article

C2 - 37523059

AN - SCOPUS:85166360235

SN - 0254-8860

VL - 42

SP - 718

EP - 723

JO - Indian Journal of Gastroenterology

JF - Indian Journal of Gastroenterology

IS - 5

ER -

Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this